AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01093053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
Study NCT03877692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental dosing of labetalol
Description: Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
Study NCT03877692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing of labetalol
Description: Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
Study NCT03086460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1531 pMDI
Description: Dose Response: Test one of five different doses of CHF 1531
Study NCT03086460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Inhalation Solution
Description: Active Control
Study NCT03086460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pMDI
Description: Matched Placebo
Study NCT03647293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Central Catheter Insertion
Study NCT03647293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripherally Inserted Central Catheter
Study NCT00905528 — intervention group
Intervention type: DRUG
Intervention: Telmisartan 80 mg/d
Study NCT00905528 — intervention group
Intervention type: DRUG
Intervention: Ramipril 10 mg/d
Study NCT04229225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular (IA) injection
Study NCT04229225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intra-articular (IA) injection
Study NCT00283608 — intervention group
Intervention type: GENETIC
Intervention: Single nucleotide polymorphism (SNP)
Description: Evaluating SNP association with traits.
Study NCT00709592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PBSCT or BMT
Description: Undergo allogeneic PBSCT or BMT
Study NCT00283608 — intervention group
Intervention type: OTHER
Intervention: high performance liquid chromatography
Description: analysis of plasma concentrations of drugs
Study NCT01786109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
Study NCT00283608 — intervention group
Intervention type: OTHER
Intervention: measurements by DXA
Description: determine bone mineral density (BMD)
Study NCT00283608 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: determine attitude changes
Study NCT02844660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiCord
Description: Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
Study NCT02844660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: moist wound therapy and offloading
Study NCT03615105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated total body irradiation
Description: Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 5 mg/kg IV
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg IV
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (adult/ped dose)
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m2 IV
Study NCT03615105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 20-30 mg/m2 IV
Study NCT03615105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
Study NCT03004846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ointment
Description: It will be supplied as white to off-white vehicle ointment for topical application.
Study NCT03035812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkali
Description: Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Study NCT04609384 — intervention group
Intervention type: DEVICE
Intervention: Alcohol rub timer device
Description: A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
Study NCT01786109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match study drug; taken as one dose orally with water.
Study NCT03705611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self-testing only
Description: Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
Study NCT03705611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing secondary accuracy
Description: A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
Study NCT03428204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon dilation during 180 seconds
Description: Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
Study NCT03428204 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon dilation during 300 seconds
Description: Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
Study NCT06059079 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT03850587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: comparator medication
Study NCT03850587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 37.5Mg+ Celecoxib 200mg
Description: experimental medication
Study NCT03850587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 75mg+ Celecoxib 200mg
Description: experimental medication
Study NCT03850587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 150mg+ Celecoxib 200mg
Description: experimental medication
Study NCT03447795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: grafting procedure using autogenous tooth.
Study NCT00942682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Taken orally twice daily
Study NCT00942682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once daily in the morning
Study NCT01499576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy
Description: Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
Study NCT01670500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: administered intravenously every 3 weeks for 4 doses
Study NCT01670500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
Study NCT01670500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Proteasome Inhibitor
Study NCT03447795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafting procedure using autogenous tooth.
Study NCT03363035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Description: One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study NCT03363035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Description: One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study NCT03363035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Proteasome Inhibitor
Study NCT01656746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic laparoscopic surgery
Description: Undergo single incision laparoscopic surgery
Study NCT02729168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rabies vaccine
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity
Study NCT04246047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity
Study NCT02722135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study NCT03219736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care therapies
Description: If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
Study NCT03219736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NiPPV Therapy
Description: If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
Study NCT03219736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Respiratory Care
Description: It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
Study NCT01166334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WebQuit study group
Description: Description withheld to protect integrity of study
Study NCT01166334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WebQuit control group
Description: Identity and description withheld to protect integrity of study
Study NCT02524678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02524678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URC102
Study NCT02086045 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Description: percutaneous coronary
Study NCT01370538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study NCT01370538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study NCT02980653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 400 mg/day
Description: Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
Study NCT01122953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
Study NCT01122953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epamin
Description: Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
Study NCT02096224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be used.
Study NCT02096224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane will be used
Study NCT04508075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine (inactivated)
Description: SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac
Study NCT04508075 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured by PT. Bio Farma
Study NCT04667169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemorrhoidal Artery Ligation
Description: Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
Study NCT04667169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidoplasty
Description: Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
Study NCT03678662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoalgesia expectation
Description: Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information.
Study NCT03678662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperalgesia expectation
Description: Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information.
Study NCT03678662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral
Description: Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.
Study NCT02959606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate SR 300mg
Study NCT02959606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT04424680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Care Planning program of health decisions
Description: Application of an Advanced Care Planning program program for decision-making in patients with advanced Heart Failure, in comparison to usual follow up and care.
Study NCT04099420 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle counseling
Description: An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
Study NCT01170130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (sterile)
Description: during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
Study NCT01076933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Stimulation Magnetic (rTMS)
Description: The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
Study NCT01076933 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks
Study NCT01405911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Description: 1 tablet orally once daily before breakfast for 8 weeks